{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:33:54Z","timestamp":1769668434594,"version":"3.49.0"},"reference-count":50,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: This study investigates the biochemical impact of low molecular weight heparin (LMWH) on key immunological, coagulation, and inflammatory markers in patients with hyperlipidemic acute pancreatitis (HLAP). The objective is to elucidate the role of LMWH in modulating serum immunoglobulins (IgA, IgG, IgM), coagulation parameters (PT, TT, FIB, APTT), proinflammatory cytokines (TNF-a, IL-6, IL-8), and digestive enzyme activity (amylase), thereby providing insight into its therapeutic mechanism. Methods: A total of 100 HLAP patients treated between January 2022 and December 2024 were assigned to a control group (CG) receiving standard medical treatment, and an experimental group (EG) receiving standard treatment plus LMWH. Biomolecular markers were analysed to assess changes in coagulation dynamics, inflammatory signalling, immunoglobulin response, and lipid metabolism. Comparative analysis between groups was conducted to evaluate the biochemical effects of LMWH. Results: Compared to the control group, the LMWH-treated group demonstrated significant reductions in inflammatory mediators: TNF-a decreased by 38.2%, IL-6 by 34.5%, and IL-8 by 36.7% (all P&amp;lt;0.01). Serum amylase and urinary amylase levels declined by 41.3% and 39.6%, respectively (P&amp;lt;0.01). Coagulation profiles improved with PT prolonged by 13.8%, TT by 15.2%, FIB reduced by 12.4%, and APTT normalised by a 17.1% increase (P&amp;lt;0.01). Immune markers IgA, IgG, and IgM increased by 22.5%, 26.3%, and 24.8%, respectively (P&amp;lt;0.01). Additionally, the LMWH group showed better lipid regulation (TG reduced by 45.7%) and a lower complication rate (6% vs. 22%, P=0.02). Conclusions: LMWH exhibits a multifaceted biochemical effect in HLAP patients, encompassing anti-inflammatory action, immunomodulation, and correction of coagulation abnormalities. These findings support LMWH as a potential adjunctive therapeutic agent in the biochemical management of HLAP warranting further molecular studies to explore its mechanistic pathways.<\/jats:p>","DOI":"10.5937\/jomb0-58836","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T08:07:08Z","timestamp":1752221228000},"page":"177-189","source":"Crossref","is-referenced-by-count":0,"title":["Effects of low molecular weight heparin on inflammatory, coagulation, and immune markers in hyperlipidemic acute pancreatitis"],"prefix":"10.5937","volume":"45","author":[{"given":"Yujie","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Yancheng Third People's Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University), Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinchao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yancheng Third People's Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University), Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yancheng Third People's Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University), Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yancheng Third People's Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University), Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yancheng Third People's Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University), Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yancheng Third People's Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University), Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Shaker Al-Awady M, Mohammed Ali B. Effect of vitamin D supplementation on glycemic control in type 1 diabetes mellitus. Cell Mol Biomed Rep 2024; 4(4): 189-98;","DOI":"10.55705\/cmbr.2024.436594.1218"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Swapna B, Fathima K, Muwayyad H, Khanam M, Salma S, Harsha S, et al. A study to assess the associated risk of developing cardiovascular diseases in chronic kidney disease. Cell Mol Biomed Rep 2024; 4(3): 150-8;","DOI":"10.55705\/cmbr.2023.420751.1184"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Talebi Mehrdar M, Ebadi G. Increased levels of serum Adenosine deaminase (ADA) enzyme and increased risk of T cell activation markers in type 2 diabetes. Cell Mol Biomed Rep 2024; 4(3): 159-67;","DOI":"10.55705\/cmbr.2023.423332.1186"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Wang J, Xia Y, Cao Y, Cai X, Jiang S, Liao Y, et al. Evaluating the efficacy and timing of blood purification modalities in early-stage hyperlipidemic acute pancreatitis treatment. Lipids Health Dis 2023; 22(1): 208;","DOI":"10.1186\/s12944-023-01968-z"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology 2020; 20(5): 795-800;","DOI":"10.1016\/j.pan.2020.06.005"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Lin YF Yao Y Xu Y Huang HB. Apheresis Technique for Acute Hyperlipidemic Pancreatitis: A Systemic Review and Meta-Analysis. Dig Dis Sci 2023; 68(3): 948-56;","DOI":"10.1007\/s10620-022-07545-1"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Pu W, Tang W, Shen Y Ji F Huang J, Liu Y et al. Comparison of different intensive triglyceride-lowering therapies in patients with hyperlipidemic acute pancreatitis. Pancreatology 2023; 23(8): 919-25;","DOI":"10.1016\/j.pan.2023.10.003"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"D'Alessio A, Marchetti M, Tartari CJ, Russo L, Cecchini S, Lambregts K, et al. Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. Cancer Investigation 2017; 35(7): 490-9;","DOI":"10.1080\/07357907.2017.1340480"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Vitiello A, Ferrara F Low Molecular Weight Heparin, Anti-inflammatory\/Immunoregulatory and Antiviral Effects, a Short Update. Cardiovasc Drugs Ther 2023; 37(2): 277-81;","DOI":"10.1007\/s10557-021-07251-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Stefanutti C, Labbadia G, Morozzi C. Severe hypertriglyceridemia-related acute pancreatitis. Ther Apher Dial 2013; 17(2): 130-7;","DOI":"10.1111\/1744-9987.12008"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Wei B, Su Z, Yang H, Feng Y Meng C, Liang Z. Inhibition of TRAF6 improves hyperlipidemic acute pancreatitis by alleviating pyroptosis in vitro and in vivo rat models. Biology Direct 2023; 18(1): 23;","DOI":"10.1186\/s13062-023-00380-y"},{"key":"ref12","unstructured":"Chen EX, Tong JH, Che G, She ZF Cao X. Comparison between oral and enteral tube refeeding in hyperlipidemic acute pancreatitis. Eur Rev Med Pharmacol Sci 2023; 27(19): 9309-14;"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kyriakidis AV Raitsiou B, Sakagianni A, Harisopoulou V , Pyrgioti M, Panagopoulou A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73(4): 259-64;","DOI":"10.1159\/000095425"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Glaubitz J, Asgarbeik S, Lange R, Mazloum H, Elsheikh H, Weiss FU, et al. Immune response mechanisms in acute and chronic pancreatitis: strategies for therapeutic intervention. Front Immunol 2023; 14: 1279539;","DOI":"10.3389\/fimmu.2023.1279539"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lechner J, Rudi T von Baehr V . Osteoimmunology of tumor necrosis factor-alpha, IL-6, and RANTES\/CCL5: a review of known and poorly understood inflammatory patterns in osteonecrosis. Clin Cosmet Investig Dent 2018; 10: 251-62;","DOI":"10.2147\/CCIDE.S184498"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, et al. The Role of Tumor Necrosis Factor Alpha (TNF-a) in Autoimmune Disease and Current TNF-a Inhibitors in Therapeutics. Int J Mol Sci 2021; 22(5);","DOI":"10.3390\/ijms22052719"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Liu G, Liu F Xiao L, Kuang Q, He X, Wang Y, et al. Treatment of hyperlipidemic acute pancreatitis with modified Dachengqi decoction combining with conventional therapy based on \"six-hollow-organs to be unblocked\" theory. Ann Palliat Med 2020; 9(4): 2045-53;","DOI":"10.21037\/apm-20-1106"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zhou W, Liu Q, Wang Z, Ybo L, Chen J, Yang X. Analysis of the clinical profile and treatment efficiency of hyperlipidemic acute pancreatitis. Lipids Health Dis 2024; 23(1): 70;","DOI":"10.1186\/s12944-024-02057-5"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Costantini TW, Kornblith LZ, Pritts T Coimbra R. The intersection of coagulation activation and inflammation after injury: What you need to know. J Trauma Acute Care Surg 2024; 96(3): 347-56;","DOI":"10.1097\/TA.0000000000004190"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Kohs TCL, Vu HH, Jordan KR, Parra-Izquierdo I, Hinds MT Shatzel JJ, et al. Activation of coagulation FXI promotes endothelial inflammation and amplifies platelet activation in a nonhuman primate model of hyperlipidemia. Res Pract Thromb Haemost 2024; 8(1): 102276;","DOI":"10.1016\/j.rpth.2023.102276"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Gu X, Huang Z, Ying X, Liu X, Ruan K, Hua S, et al. Ferroptosis exacerbates hyperlipidemic acute pancreatitis by enhancing lipid peroxidation and modulating the immune microenvironment. Cell Death Discov 2024; 10(1): 242;","DOI":"10.1038\/s41420-024-02007-1"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Chen K, Magri G, Grasset EK, Cerutti A. Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA. Nat Rev Immunol 2020; 20(7): 427-41;","DOI":"10.1038\/s41577-019-0261-1"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Moon SJ, Ko RE, Park CM, Suh GY, Hwang J, Chung CR. The Effectiveness of Early Enteral Nutrition on Clinical Outcomes in Critically Ill Sepsis Patients: A Systematic Review. Nutrients 2023; 15(14);","DOI":"10.3390\/nu15143201"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Baiu I, Spain DA. Parenteral Nutrition. Jama 2019; 321(21): 2142;","DOI":"10.1001\/jama.2019.4410"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Robinson S, Zincuk A, Str0m T Larsen TB, Rasmussen B, Toft R Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 2010; 14(2): R41;","DOI":"10.1186\/cc8924"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Thind T Heye T Henson C, Reif R, Jensen HK, Kalkwarf KJ, et al. Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma Patients. Am Surg 2024; 90(6): 1406-11;","DOI":"10.1177\/00031348241241620"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Podda M, Murzi V, Marongiu P Di Martino M, De Simone B, Jayant K, et al. Effectiveness and safety of low molecular weight heparin in the management of acute pancreatitis: a systematic review and meta-analysis. World J Emerg Surg 2024; 19(1): 30;","DOI":"10.1186\/s13017-024-00558-3"},{"key":"ref28","unstructured":"Tozlu M, Kayar Y ince AT, Baysal B, \u00c7ent\u00fcrk H. Low molecular weight heparin treatment of acute moderate and severe pancreatitis: A randomised, controlled, open-label study. Turk J Gastroenterol 2019; 30(1): 81-7;"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Yin G, Cang X, Yu G, Hu G, Ni J, Xiong J, et al. Different Clinical Presentations of Hyperlipidemic Acute Pancreatitis: A Retrospective Study. Pancreas 2015; 44(7): 1105-10;","DOI":"10.1097\/MPA.0000000000000403"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"D\u00fczenli T. Comparison of treatments in patients with hyperlipidemic acute pancreatitis. Pancreatology 2024; 24(3): 497;","DOI":"10.1016\/j.pan.2024.02.017"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Chen G, Huang Y Yu H, Wang J, Li H, Shen S, et al. Nanoparticles Fueled by Enzyme for the Treatment of Hyperlipidemic Acute Pancreatitis. ACS Biomater Sci Eng 2024; 10(11): 7176-90;","DOI":"10.1021\/acsbiomaterials.4c00474"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Wang HL, Yu KJ. Sequential blood purification therapy for critical patients with hyperlipidemic severe acute pancreatitis. World J Gastroenterol 2015; 21(20): 6304-9;","DOI":"10.3748\/wjg.v21.i20.6304"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Wang P Chi L, Zhang Z, Zhao H, Zhang F , Linhardt R J. Heparin: An old drug for new clinical applications. Carbohydr Polym 2022; 295: 119818;","DOI":"10.1016\/j.carbpol.2022.119818"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(1 Suppl): 64s-94s;","DOI":"10.1378\/chest.119.1_suppl.64S"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Rosenberg K. Low-Dose Low-Molecular-Weight Heparin for Thromboprophylaxis During Pregnancy. Am J Nurs 2023; 123(3): 61;","DOI":"10.1097\/01.NAJ.0000921828.47893.d9"},{"key":"ref36","unstructured":"Ageno W, Turpie AG. Low-molecular-weight heparin in the treatment of pulmonary embolism. Seminars in vascular surgery 2000; 13(3): 189-93;"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Patoni C, Bunduc S, Frim L, Veres DS, Dembrovszky F Elias AJ, et al. Low molecular weight heparin decreases mortality and major complication rates in moderately severe and severe acute pancreatitis-a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10: 1241301;","DOI":"10.3389\/fmed.2023.1241301"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Jabto ska B, Mrowiec S. Nutritional Support in Patients with Severe Acute Pancreatitis-Current Standards. Nutrients 2021; 13(5);","DOI":"10.3390\/nu13051498"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Arvanitakis M, Ockenga J, Bezmarevic M, Gianotti L, Krznari Z, Lobo DN, et al. ESPEN practical guideline on clinical nutrition in acute and chronic pancreatitis. Clin Nutr 2024; 43(2): 395-412;","DOI":"10.1016\/j.clnu.2023.12.019"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Yang XJ, Wang XH, Yang MY, Ren HY, Chen H, Zhang XY, et al. Exploring choices of early nutritional support for patients with sepsis based on changes in intestinal microecology. World J Gastroenterol 2023; 29(13): 2034-49;","DOI":"10.3748\/wjg.v29.i13.2034"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Cruz-Lemini M, Vazquez JC, Ullmo J, Llurba E. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis. Am J Obstet Gynecol 2022; 226(2s): S1126-S44.e17;","DOI":"10.1016\/j.ajog.2020.11.006"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Urashima Y, Ueno T, Takeda C, Kusaba H, Tanaka R, Noda K, et al. Study on enteral nutrient components causing decreased gastric phenytoin absorption. JPEN J Parenter Enteral Nutr 2023; 47(7): 911-9;","DOI":"10.1002\/jpen.2542"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Bukowski JS, Dembi ski L, Dziekiewicz M, Banaszkiewicz A. Early Enteral Nutrition in Paediatric Acute Pancreatitis-A Review of Published Studies. Nutrients 2022; 14(16);","DOI":"10.3390\/nu14163441"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Parvizi J, DeMik DE, Dunbar M, Hozack WJ, Mont MA, Lachiewicz PE Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It? J Bone Joint Surg Am 2022; 104(23): 2045-6;","DOI":"10.2106\/JBJS.22.01024"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Yang M, Liu J. Low-molecular weight heparin prevents portal vein system thrombosis after splenectomy: a systematic review and meta-analysis. ANZ J Surg 2020; 90(12): 2420-4;","DOI":"10.1111\/ans.15865"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Schriner JB, Triolo F Gill BS, Cardenas JC, Olson SD, Cox CS, Jr. Low molecular weight heparin decreases procoagulant activity in clinical MSC products. Cytotherapy 2024; 26(2): 194-200;","DOI":"10.1016\/j.jcyt.2023.11.010"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Kashiwagi S, Kanda N, Yoshida M, Wakimoto Y, Ohbe H, Nakamura K. Effects of early enteral nutrition on persistent inflammation, immunosuppression, and catabolism syndrome in critically ill patients: A claims database study using a propensity score analysis. Clin Nutr 2024; 43(8): 1872-9;","DOI":"10.1016\/j.clnu.2024.06.033"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Reintam Blaser A, Starkopf J, Alhazzani W, Berger MM, Casaer MR Deane AM, et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med 2017; 43(3): 380-98;","DOI":"10.1007\/s00134-016-4665-0"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Zhang H, Wang Y, Sun S, Huang X, Tu G, Wang J, et al. Early enteral nutrition versus delayed enteral nutrition in patients with gastrointestinal bleeding: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019; 98(11): e14864;","DOI":"10.1097\/MD.0000000000014864"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Wiemer J, Winkler K, Baumstark M, Marz W, Scherberich JE. Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Nephrol Dial Transplant 2002; 17(12): 2231-8;","DOI":"10.1093\/ndt\/17.12.2231"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Efekti heparina niske molekularne mase na inflamatorne, koagulacione i imunolo\u0161ke markere kod hiperlipidemijskog akutnog pankreatitisa"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582601177L.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T17:56:45Z","timestamp":1769623005000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582601177L"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-58836","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}